Press releases from the 26th EORTC – NCI – AACR symposium on molecular targets in cancer therapeutics in Barcelona

The 26th EORTC – NCI – AACR symposium on molecular targets in cancer therapeutics recently held in Barcelona proved to be a very successful event. Below is a listing of some of the many results announced at this prestigious symposium:

• Early results of new drug, ASP8273, show response in Japanese patients with treatment-resistant non-small cell lung cancer
• Researchers pioneer new approach to treating HPV-related cervical cancer
• Researchers identify biological indicator of response to new ovarian cancer drug
• Early results show response to new drug in patients with lymphomas and advanced solid tumours
• Three drugs may be better than one for certain patients with advanced colorectal cancer
• Trial results show treatment-resistant advanced non-small cell lung cancer responds to new drug, rociletinib
• Patients with advanced papillary kidney cancer respond well to a combination of two existing anti-cancer drugs
• Galeterone shows activity in a variant form of castration-resistant prostate cancer
• First demonstration of anti-cancer activity for AG-120, an inhibitor of the IDH1 mutation, in patients with advanced leukaemia